About

At Terremoto, we are creating a seismic shift in the breadth of pursuable targets. Our ultimate goal? To deliver highly targeted, small molecule medicines with optimized clinical profiles and superior therapeutic benefit.

Our Story

Breaking Open the Covalent Drug Universe

The world has witnessed incredible advances in drug development over the last two decades, including new drugs for previously intractable targets. And yet, many patients still face too few treatment options, notably in devastating conditions like cancer.

Enter covalent chemistry.

At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.

We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.

The Earth-Shakers

Founded by the Pioneers

With the deep knowledge of our founders, leadership and overall team, we have the ability to translate our ambitious vision into real treatments. Most importantly, our group has set the industry standard for rapidly delivering these medicines to patients – a record we intend to maintain with our platform approach.

Charles Baum, M.D., Ph.D.

Chief Executive Officer

James Christensen, Ph.D.

President, Head of Research & Development

Maika Adair

Director, Clinical Supply Chain, Technical Operations

Brian Bestvater

Senior Associate Scientist, Chemistry

Noleen Bonfante

Executive Director, Clinical Operations

Jordan Carelli, Ph.D.

Director, Biology

Curtis Chin, M.D., Ph.D.

Executive Medical Director

Regina Choy, Ph.D.

Senior Director, Biology & Translational Sciences

Hamlet Chu

Senior Director, Business Development

Hang Chu, Ph.D.

Executive Director, Medicinal Chemistry

Matthew Condakes

Associate Director, Medicinal Chemistry

Michael Corbett, Ph.D.

Senior Director, Head of Technical Operations

Bryan Cox, Ph.D.

Senior Director, Computational Chemistry

Brittany Coyne

Senior Associate Scientist, Biology

Courtney Daczkowski

Senior Scientist 1, Protein Sciences

Janaina Dargell

Associate Director, Human Resources

Subhamoy Das, Ph.D.

Senior Scientist 2, Biology

Mark Eskes

Senior Director, Project Management, Technical Operations

Jason Estep, Ph.D.

Senior Scientist, Biology

Rebecca Freilich, Ph.D.

Senior Scientist 2, Biology

Monika Gavireddi

Senior Scientist 2, Technical Operations

George Gindoyan

Executive Director, Information Technology and Informatics

Whitney Greenberg

Senior Associate Scientist, Technical Operations

Caroline Gundel

Research Operations Manager

Timothy Hansen

Associate Scientist, Medicinal Chemistry

Stephen Harwood, Ph.D.

Senior Scientist, Medicinal Chemistry

Renee Himes

Associate Director, Clinical Operations

Vivian Ho

Executive Director, Finance and Accounting

Karin Ku

Senior Scientist, Biology

Victor Lee

Laboratory & Facilities Associate 2

Guangtao Li, Ph.D.

Senior Director, Analytical Development/Quality Control

Melvynn Lacoste

Scientist, Technical Operations

Nikhil Loka, Ph.D.

Director, Drug Product Development, Technical Operations

Grace Lu, MBA

Chief Business Officer

Charlie Ma, Ph.D.

Senior Director, Structural Biology

Antonett Madriaga

Senior Associate Scientist, Biology

Romel Montellano, MBA

Executive Director, Regulatory Operations

Gigi Moore

Senior Executive Assistant/Office Manager

Johnson Nguyen

Senior Manager, Accounting Operations

Deborah Park

Scientist 2, Biology

Solomon Reisberg, Ph.D.

Vice President, Head of Chemistry

James Roquero

Vivarium Research Associate

Andrey Rymar

Senior Associate Scientist, Biology

Sarah Schisla

Associate Scientist, Technical Operations

Terri Schoeneman

Senior Director, Quality Assurance

Jacob Schrier, Ph.D.

Associate Director, Biology

Jane Shank

Business Manager/Senior Executive Assistant

Ronald Shazer

Senior Vice President, Head of Clinical Development

Kathleen Shiffer, Ph.D.

Laboratory & Facilities Manager

Wagner Silva

Associate Director, Clinical Operations

Nicola Stagg, Ph.D., DABT

Executive Director, Head of Toxicology

Paul Stephensen, MBA

Vice President, Accounting

Jessica Sun, Ph.D.

Executive Director, Head of In Vivo Pharmacology

Saba Tamjidi

Scientist, Biology

Pranali Taskar

Scientist, Biology

Roxanne Vega Andaya

Senior Scientist 2, Preclinical

Cora Versaggi

Senior Vice President, Human Resources

Kent Wong

Scientist, Biology

Melissa Wong

Associate Scientist, Biology

Kin Yang, Ph.D.

Executive Director, Medicinal Chemistry

Adam Zajdlik

Senior Scientist, Medicinal Chemistry

Board of Directors

Charles Baum, M.D., Ph.D.

CEO, Terremoto

James Christensen, Ph.D.

President, Head of Research & Development, Terremoto

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Daniel O’Connell, M.D., Ph.D.

Partner, Novo Holdings Venture Investments

Adam Schayowitz, Ph.D., MBA

Operating Partner, EcoR1 Capital

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed

Founders

Matthew Jacobson, Ph.D.

Professor, Dept. of Pharmaceutical Chemistry, UCSF

Jack Taunton, Ph.D.

Professor, Cellular Molecular Pharmacology, UCSF

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed Founder

Scientific Advisors

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Kevin Koch, Ph.D.

President, CEO and CFO, Edgewise
Venture Partner, OrbiMed

Jack Taunton, Ph.D.

Professor, Cellular Molecular
Pharmacology, UCSF

Matthew Jacobson, Ph.D.

Professor, Dept. of Pharmaceutical Chemistry, UCSF

John Link, Ph.D.

Former Vice President, Medicinal Chemistry, Gilead Sciences

Investors